Sign In
Buy FATE
$2.45
-0.0600 (-2.39%)
At Close: Jul 31, 2026
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
06:25pm, Tuesday, 13'th Aug 2024
Fate Therapeutics (FATE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.54 per share a year ago.
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
04:05pm, Tuesday, 13'th Aug 2024
Enrollment Ongoing with FT819 1XX CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Single-agent Cyclophosphamide Included as Alternative Conditioning Regimen
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd Aug 2024
SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
05:37am, Sunday, 21'st Jul 2024
The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 02'nd Jul 2024
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate") on behalf of the company's long-term investors. Recently
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 04'th Jun 2024
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
04:01pm, Wednesday, 29'th May 2024
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a fi
Russell Investments Group Ltd. Acquires 59,267 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)
05:04am, Monday, 20'th May 2024
Russell Investments Group Ltd. increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 34.0% during the fourth quarter, according to the company in its most re
Fate Therapeutics, Inc. Expected to Post Q2 2024 Earnings of ($0.40) Per Share (NASDAQ:FATE)
01:38am, Monday, 20'th May 2024
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 EPS estimates for Fate Therapeutics in a report released on Thursday, May 16th
Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript
06:12pm, Saturday, 11'th May 2024
Fate Therapeutics, Inc. (NASDAQ:FATE ) Q1 2024 Results Conference Call May 9, 2024 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Bob Valamehr - Chief Research and De
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
06:26pm, Thursday, 09'th May 2024
Fate Therapeutics (FATE) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
04:01pm, Thursday, 09'th May 2024
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
08:30am, Thursday, 09'th May 2024
Pre-treatment Sample of Patient's Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819
Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells
